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CommentaryThe good, the bad, and the unknown: Fructose
and FGF21wSusanna M. Hofmann 1,2,*, Peter J. Havel 3,4In this issue of Molecular Metabolism, Dushay et al. report new results
demonstrating fructose ingestion in humans acutely and robustly rai-
ses circulating levels of ﬁbroblast growth factor 21 (FGF21) [1], a
recently discovered hormone that has been proposed to have beneﬁ-
cial effects on metabolic health, including reduction of body weight and
improvements of glucose and lipid metabolism [2]. People suffering
from the metabolic syndrome have higher baseline circulating FGF21
levels and exhibit a larger increase of plasma FGF21 concentrations
following an oral fructose load. In contrast, the increase of FGF21 after
ingestion of the same amount of glucose was delayed and much more
modest. These results are paradoxical in that the metabolic effects of
FGF-21 appear to be mainly beneﬁcial while those of dietary fructose
are generally deleterious [3]. The authors suggest the possibility that
obese subjects with metabolic syndrome are resistant to the actions of
FGF21 (akin to augmentation of circulating insulin and leptin con-
centrations and responses in insulin and leptin resistance) and that the
exaggerated response to fructose ingestion may be a compensatory
response [1]. The increases of FGF-21 in response to fructose
ingestion across normal weight and overweight/obese subjects was
signiﬁcantly correlated with circulating insulin and glucose levels in
response to oral glucose loads suggesting a relationship between
FGF21 and insulin senstivity/glucose tolerance. Together, these novel
results shed light on a potential mechanism related to the adverse
metabolic effects of dietary fructose and raise new questions about the
nutritional regulation of metabolic responses to dietary macronutrients,
speciﬁcally sugars.
Fructose is a major component of Western diets, and mounting evi-
dence points to an obesogenic role for fructose via generation of
substrates for de novo lipogenesis through rapid hepatic metabolism
[3]. To understand how fructose may mediate its deleterious effects on
various tissues, the authors proposed an intriguing novel hypothesis;
fructose may acutely increase the production and secretion of FGF21
by potently activating the transcription factor carbohydrate response
element-binding protein (ChREBP). In their study, Dushay et al.
monitored circulating FGF21 levels after ingestion of a large (75 g)
fructose bolus in 21 patients, half of them lean and healthy and half ofwThis commentary refers to “Fructose ingestion acutely stimulates circulating FGF21 le
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increased rapidly and sharply within 2 h and returned to baseline levels
within 5 h in all patients, the response to fructose varied widely be-
tween the subjects. These ﬁndings point to individual differences in
fructose absorption, metabolism and/or sensing. If that is the case, it
would be important to understand whether an individual’s suscepti-
bility to develop diabetes may be predicted by a fructose tolerance test.
If so, availability of such a test would help prevent onset of metabolic
disease in subjects at risk by early personalized life style intervention
and treatment.
The ﬁndings of this study are in line with previous work indicating that
consumption of fructose- or glucose-sweetened beverages with meals
produces very different, acute effects on circulating levels of endocrine
signals, including insulin, leptin, ghrelin, and glucagon-like peptide-1
(GLP-1), and triglycerides [4]. Speciﬁcally, circulating FGF21 and GLP-
1 are both increased to a greater extent and ghrelin is less suppressed
by fructose than glucose [4,5]. Now FGF21 can be added to the
growing list of endocrine and metabolic responses known to be
differentially inﬂuenced by fructose ingestion. In studies comparing
prolonged ingestion of fructose with glucose, consuming fructose-
sweetened beverages for 10 weeks increases visceral adiposity,
lipid/lipoprotein risk factors for cardiovascular disease, decreases in-
sulin senstitivity, and increases uric acid and markers of inﬂammation
to a greater extent than glucose [6e8] and increases hepatic lipid
deposition [9]. The effects of prolonged chronic ingestion of dietary
sugars on circulating FGF21 and FGF21 responses to nutrient inges-
tion, however, are not known.
In the present study, a large dose of pure fructose (75 g) was ingested
by the study subjects. Dietary fructose is typically consumed as a
mixture of glucose and fructose in the form of high-fructose corn syrup
(HFCS) or sucrose. The authors addressed this by examining the ef-
fects of a mixed glucose/fructose load on FGF-21 responses, and the
mixture increased plasma FGF-21 similarly to pure fructose, by itself.
Similarly, the mixture of fructose and glucose in HFCS increases lipid
and lipoprotein risk factors for CVD extent as pure fructose [10]. A
recent study in mice fed HFCS for 14 weeks reporting increases ofvels in humans by Jody R. Dushay et al.”, http://dx.doi.org/10.1016/j.molmet.2014.
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CommentaryFGF21 expression in muscle [11] may conﬁrm a potential role for
FGF21 in fructose-mediated effects on metabolism. Thus, the current
study warrants further research to understand how FGF21 may be
related to clinical disease outcomes attributable to the consumption of
large quantities of fructose-containing sugars contained in typical
Western diets. This is of particular importance since FGF21 has been
shown to protect against diet-induced obesity, lower circulating
glucose and triglyceride levels, and increase energy expenditure, fat
utilization and lipid excretion when administered to diabetic and diet-
induced obese rodents (for a review, see 2).
In search of underlying mechanisms, the hypothesis raised by the
authors that fructose increases FGF21 production by activating the
transcription factor ChREBP points to an emerging role for ChREBP as a
control lever for certain metabolic effects of dietary fructose. A recent
report by Erion et al. suggests just that, demonstrating that targeting
ChREBP prevents fructose-induced hypertriglyceridemia but does not
improve hepatic steatosis or hepatic insulin resistance in rats [12]. In
summary, Dushay and colleagues have successfully highlighted a
complex new area of interplay between a potentially beneﬁcial hor-
mone, FGF-21, and the dietary nutrient fructose with adverse meta-
bolic effects. The details of this interaction will need to be sorted out
prior to the development of novel drugs targeting metabolic pathways
regulated by fructose. Accordingly, if FGF-21 is “the good“ and fruc-
tose is “the bad“, the nutrient-endocrine interface between the two
remains “the unknown“.
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